Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lung hyperinflation refers to an abnormal increase in lung volume caused by trapped air that cannot be exhaled effectively. This leads to overexpansion of the lungs beyond their normal size. The condition most frequently arises from chronic obstructive pulmonary disease (COPD), where damage to alveoli and narrowing/inflammation of airways prevent complete exhalation. It can also occur with asthma, cystic fibrosis, bronchiectasis, and bronchiolitis. Symptoms include shortness of breath and reduced exercise capacity; diagnosis relies on imaging studies such as chest X-rays or CT scans showing increased total lung capacity or functional residual capacity. Treatment focuses on managing underlying diseases with medications like bronchodilators and inhaled steroids; advanced cases may require oxygen therapy or surgery.
Drugs aim to reduce airway inflammation and obstruction to improve airflow and decrease air trapping. Bronchodilators relax airway smooth muscle; corticosteroids reduce inflammation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lung hyperinflation.